Europe and the UK have experienced an uneven rollout of vaccines. In today's episode, our country risk and life science experts come together to talk about supply chain challenges, heightened protectionist moments, enhanced regulatory reviews, and even strange vaccine bedfellows as some countries turn to Russia's Sputnik vaccine to push along herd immunity. Lindsay Newman (Moderator), Director, Economics & Country Risk, IHS Markit https://experts.ihsmarkit.com/experts/newman-lindsay Eoin Ryan, Senior Analyst, Life Sciences, IHS Markit https://experts.ihsmarkit.com/experts/ryan-eoin Diego Iscaro, Senior European Economist, IHS Markit https://experts.ihsmarkit.com/experts/iscaro-diego Dijedon Imeri, Senior Country Risk Analyst, IHS Markit https://experts.ihsmarkit.com/experts/imeri-dijedon Learn more additional risk to vaccine rollouts: Vaccine hesitancy boosts risks from vaccine nationalism https://ihsmarkit.com/research-analysis/vaccine-hesitancy-boosts-risks-from-vaccine-nationalism.html The risks of vaccine nationalism https://ihsmarkit.com/research-analysis/the-risk-of-vaccine-nationalism.html

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.